SEARCH

SEARCH BY CITATION

References

  • Amadoro G., Ciotti M. T., Costanzi M., Cestari V., Calissano P. and Canu N. (2006) NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proc. Natl Acad. Sci. USA 103, 28922897.
  • Anderson K. L. and Ferreira A. (2004) α1-Integrin activation: a link between beta-amyloid deposition and neuronal death in aging hippocampal neurons. J. Neurosci. Res. 75, 688697.
  • Bell K. A., O’Riordan K. J., Sweatt J. D. and Dineley K. T. (2004) MAPK recruitment by beta-amyloid in organotypic hippocampal slice cultures depends on physical state and exposure time. J. Neurochem. 91, 349361.
  • Brendza R. P., Bacskai B. J., Cirrito J. R. et al. (2005) Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J. Clin. Invest. 115, 428433.
  • Calon F., Lim G. P., Yang F. et al. (2004) Docosahexaenoic acid protects from dendritic pathology in an Alzheimer’s disease mouse model. Neuron 43, 633645.
  • Calon F., Lim G. P., Morihara T., Yang F., Ubeda O., Salem N. J., Frautschy S. A. and Cole G. M. (2005) Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer’s disease. Eur. J. Neurosci. 22, 617626.
  • Chromy B. A., Nowak R. J., Lambert M. P. et al. (2003) Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 42, 1274912760.
  • Cleary J. P., Walsh D. M., Hofmeister J. J., Shankar G. M., Kuskowski M. A., Selkoe D. J. and Ashe K. H. (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8, 7984.
  • Cole G. M., Yang F., Lim G. P., Cummings J. L., Masterman D. L. and Frautschy S. A. (2003) A rationale for curcuminoids for the prevention or treatment of Alzheimer’s disease. Curr. Med. Chem-Immun. Endoc. Metab. Agents 3, 1525.
  • Costa R. M., Federov N. B., Kogan J. H., Murphy G. G., Stern J., Ohno M., Kucherlapati R., Jacks T. and Silva A. J. (2002) Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 415, 526530.
  • Daniels W. M., Hendricks J., Salie R. and Taljaard J. J. (2001) The role of the MAP-kinase superfamily in beta-amyloid toxicity. Metab. Brain Dis. 16, 175185.
  • Dineley K. T., Westerman M., Bui D., Bell K., Ashe K. H. and Sweatt J. D. (2001) Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer’s disease. J. Neurosci. 21, 41254133.
  • Echeverria V., Ducatenzeiler A., Dowd E. et al. (2004) Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the beta-amyloid peptide intracellularly in hippocampal and cortical neurons. Neuroscience 129, 583592.
  • Echeverria V., Ducatenzeiler A., Chen C. H. and Cuello A. C. (2005) Endogenous beta-amyloid peptide synthesis modulates cAMP response element-regulated gene expression in PC12 cells. Neuroscience 135, 11931202.
  • English J. D. and Sweatt J. D. (1997) A requirement for the mitogen-activated protein kinase cascade in hippocampal long term potentiation. J. Biol. Chem. 272, 1910319106.
  • Frautschy S. A., Hu W., Miller S. A., Kim P., Harris-White M. E. and Cole G. M. (2001) Phenolic anti-inflammatory antioxidant reversal of Ab-induced cognitive deficits and neuropathology. Neurobiol. Aging 22, 9911003.
  • Garcia-Estrada J., Garcia-Segura L. M. and Torres-Aleman I. (1992) Expression of insulin-like growth factor I by astrocytes in response to injury. Brain Res. 592, 343347.
  • Goldin M. and Segal M. (2003) Protein kinase C and ERK involvement in dendritic spine plasticity in cultured rodent hippocampal neurons. Eur. J. Neurosci. 17, 25292539.
  • Gong B., Vitolo O. V., Trinchese F., Liu S., Shelanski M. and Arancio O. (2004) Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J. Clin. Invest. 114, 16241634.
  • Gong B., Cao Z., Zheng P., Vitolo O. V., Liu S., Staniszewski A., Moolman D., Zhang H., Shelanski M. and Arancio O. (2006) Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 126, 775788.
  • Greenamyre J. T., Penney J. B., D’Amato C. J. and Young A. B. (1987) Dementia of the Alzheimer’s type: changes in hippocampal L-[3H]glutamate binding. J. Neurochem. 48, 543551.
  • Hock C., Konietzko U., Streffer J. R. et al. (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron 38, 547554.
  • Hyman B. T., Elvhage T. E. and Reiter J. (1994) Extracellular signal regulated kinases: localization of protein and mRNA in the human hippocampal formation in Alzheimer’s disease. Am. J. Pathol. 144, 565572.
  • Irizarry M. C., McNamara M., Fedorchak K., Hsiao K. and Hyman B. T. (1997) APPsw Transgenic mice develop age-related Ab deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 56, 965973.
  • Jang J. H. and Surh Y. J. (2005) Beta-amyloid-induced apoptosis is associated with cyclooxygenase-2 up-regulation via the mitogen-activated protein kinase-NF-kappaB signaling pathway. Free Radic. Biol. Med. 38, 16041613.
  • Jin Y., Yan E. Z., Fan Y., Zong Z. H., Qi Z. M. and Li Z. (2005) Sodium ferulate prevents amyloid-beta-induced neurotoxicity through suppression of p38 MAPK and upregulation of ERK-1/2 and Akt/protein kinase B in rat hippocampus. Acta Pharmacol. Sin 26, 943951.
  • Johnson-Farley N. N., Travkina T. and Cowen D. S. (2006) Cumulative activation of akt and consequent inhibition of glycogen synthase kinase-3 by brain-derived neurotrophic factor and insulin-like growth factor-1 in cultured hippocampal neurons. J. Pharmacol. Exp. Ther. 316, 10621069.
  • Kayed R., Head E., Thompson J. L., McIntire T. M., Milton S. C., Cotman C. W. and Glabe C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486489.
  • Kazanis I., Giannakopoulou M., Philippidis H. and Stylianopoulou F. (2004) Alterations in IGF-I, BDNF and NT-3 levels following experimental brain trauma and the effect of IGF-I administration. Exp. Neurol. 186, 221234.
  • Klyubin I., Walsh D. M., Lemere C. A. et al. (2005) Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11, 556561.
  • Krapivinsky G., Krapivinsky L., Manasian Y., Ivanov A., Tyzio R., Pellegrino C., Ben-Ari Y., Clapham D. E. and Medina I. (2003) The NMDA receptor is coupled to the ERK pathway by a direct interaction between NR2B and RasGRF1. Neuron 40, 775784.
  • Kumar-Singh S., Dewachter I., Moechars D. et al. (2000) Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation. Neurobiol. Dis. 7, 922.
  • Kurino M., Fukunaga K., Ushio Y. and Miyamoto E. (1995) Activation of mitogen-activated protein kinase in cultured rat hippocampal neurons by stimulation of glutamate receptors. J. Neurochem. 65, 12821289.
  • Lesne S., Koh M. T., Kotilinek L., Kayed R., Glabe C. C., Yang A., Gallagher M. and Ashe K. H. (2006) A specific amyloid-b assembly in the brain impairs memory. Nature 440, 352357.
  • Lim G. P., Yang F., Chu T. et al. (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s Disease. J. Neurosci. 20, 57095714.
  • Logan A., Frautschy S. A., Gonzalez A. M., Sporn M. B. and Baird A. (1992) Enhanced expression of transforming growth factor b1 in the rat brain after a localized cerebral injury. Brain Res. 587, 216225.
  • Lue L. F., Kuo Y. M., Roher A. E., Brachova L., Shen Y., Sue L., Beach T., Kurth J. H., Rydel R. E. and Rogers J. (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am. J. Pathol. 155, 853862.
  • Ma Q. L., Lim G. P., Harris-White M. E., Yang F., Ambegaokar S. S., Ubeda O. J., Glabe C. G., Teter B., Frautschy S. A. and Cole G. M. (2006) Antibodies against beta-amyloid reduce abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J. Neurosci. Res. 83, 374384.
  • Magrane J., Christensen R. A., Rosen K. M., Veereshwarayya V. and Querfurth H. W. (2006) Dissociation of ERK and Akt signaling in endothelial cell angiogenic responses to beta-amyloid. Exp. Cell Res. 312, 9961010.
  • McLean C. A., Cherny R. A., Fraser F. W., Fuller S. J., Smith M. J., Beyreuther K., Bush A. I. and Masters C. L. (1999) Soluble pool of Ab amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann. Neurol. 46, 860866.
  • Mishizen-Eberz A. J., Rissman R. A., Carter T. L., Ikonomovic M. D., Wolfe B. B. and Armstrong D. M. (2004) Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer’s disease pathology. Neurobiol. Dis. 15, 8092.
  • Monteiro F. A., Sousa M. M., Cardoso I., Do Amaral J. B., Guimaraes A. and Saraiva M. J. (2006) Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy. J. Neurochem. 97, 151161.
  • Morgan D., Diamond D. M., Gottschall P. E. et al. (2000) Ab peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 408, 982985.
  • Mucke L., Masliah E., Yu G. Q., Mallory M., Rockenstein E. M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K. and McConlogue L. (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 40504058.
  • Shackelford D. A. and Yeh R. Y. (2006) Modulation of ERK and JNK activity by transient forebrain ischemia in rats. J. Neurosci. Res. 83, 476488.
  • Sheng J. G., Price D. L. and Koliatsos V. E. (2002) Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of Abeta amyloidosis. J. Neurosci. 22, 97949799.
  • Snyder E. M., Nong Y., Almeida C. G. et al. (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 8, 10511058.
  • Sweatt J. D. (2004) Mitogen-activated protein kinases in synaptic plasticity and memory. Curr. Opin. Neurobiol. 14, 311317.
  • Tang Y. P., Shimizu E., Dube G. R., Rampon C., Kerchner G. A., Zhuo M., Liu G. and Tsien J. Z. (1999) Genetic enhancement of learning and memory in mice. Nature 401, 6369.
  • Tong L., Balazs R., Thornton P. L. and Cotman C. W. (2004) Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J. Neurosci. 24, 67996809.
  • Watanabe S., Hoffman D. A., Migliore M. and Johnston D. (2002) Dendritic K+ channels contribute to spike-timing dependent long-term potentiation in hippocampal pyramidal neurons. Proc. Natl Acad. Sci. USA 99, 83668371.
  • Webster B., Hansen L., Adame A., Crews L., Torrance M., Thal L. and Masliah E. (2006) Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. J. Neuropathol. Exp. Neurol. 65, 142151.
  • Wilcock D. M., Rojiani A., Rosenthal A. et al. (2004) Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 24, 61446151.
  • Willaime-Morawek S., Arbez N., Mariani J. and Brugg B. (2005) IGF-I protects cortical neurons against ceramide-induced apoptosis via activation of the PI-3K/Akt and ERK pathways; is this protection independent of CREB and Bcl-2? Brain Res. Mol. Brain Res. 142, 97106.
  • Xia Z., Dudek H., Miranti C. K. and Greenberg M. E. (1996) Calcium influx via the NMDA receptor induces immediate early gene transcription by a MAP kinase/ERK-dependent mechanism. J. Neurosci. 16, 54255436.
  • Xie C. W. (2004) Calcium-regulated signaling pathways: role in amyloid beta-induced synaptic dysfunction. Neuromolecular Med. 6, 5364.
  • Yamamoto-Sasaki M., Ozawa H., Saito T., Rosler M. and Riederer P. (1999) Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res. 824, 300303.
  • Yang F., Mak K., Vinters H. V., Frautschy S. A. and Cole G. M. (1994) Monoclonal antibody to the C-terminus of b-amyloid. Neuroreport 15, 21172120.
  • Yang F., Lim G. P., Begum A. N. et al. (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 58925901.
  • Ying S. W., Futter M., Rosenblum K., Webber M. J., Hunt S. P., Bliss T. V. and Bramham C. R. (2002) Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: requirement for ERK activation coupled to CREB and upregulation of Arc synthesis. J. Neurosci. 22, 15321540.
  • Zhao L., Teter B., Morihara T., Lim G. P., Ambegaokar S. S., Ubeda O. J., Frautschy S. A. and Cole G. M. (2004) Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer’s disease intervention. J. Neurosci. 24, 1112011126.
  • Zhao L., Ma Q. L., Calon F. et al. (2006) Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat. Neurosci. 9, 234242.
  • Zhu X., Lee H. G., Raina A. K., Perry G. and Smith M. A. (2002) The role of mitogen-activated protein kinase pathways in Alzheimer’s disease. Neurosignals 11, 270281.
  • Zhuang S. and Schnellmann R. G. (2006) A death-promoting role for extracellular signal-regulated kinase. J. Pharmacol. Exp. Ther. 319, 991997.